Now is Not Soon Enough: Why Improving Patient Diversity in HF Trials is a Key Priority

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Grant Support/Research Contract - Novartis; Boehringer Ingelheim